CytomX Therapeutics (CTMX) Cash from Investing Activities Growth (1y) (2015 - 2026)
CytomX Therapeutics (CTMX) Cash from Investing Activities Growth (1y) (2015 - 2026) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 62.68% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -674.01% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -166.24% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | CytomX Therapeutics | 582.34 Mn | 235.63 Mn | - | -730.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -730.07% |
| Dec 31, 2025 | -195.27% |
| Sep 30, 2025 | -97.58% |
| Jun 30, 2025 | -454.96% |
| Mar 31, 2025 | -31.83% |
| Dec 31, 2024 | 17.64% |
| Sep 30, 2024 | 142.31% |
| Jun 30, 2024 | -17.39% |
| Mar 31, 2024 | 130.61% |
| Dec 31, 2023 | -87.11% |
| Sep 30, 2023 | -10,372.68% |
| Jun 30, 2023 | 6,420.39% |
| Mar 31, 2023 | -19,824.18% |
| Dec 31, 2022 | 40,842.04% |
| Sep 30, 2022 | -104.21% |
| Jun 30, 2022 | 99.10% |
| Mar 31, 2022 | -101.25% |
| Dec 31, 2021 | -101.26% |
| Sep 30, 2021 | 110.81% |
| Jun 30, 2021 | -193.04% |